BACKGROUND: Efficacy of nusinersen in adult 5q-spinal muscular atrophy (SMA) patients regarding motor function has recently been demonstrated. However, additional outcome measures are needed to capture non-motor improvements. Fatigue is a common and disabling symptom in neurologic diseases, but little is known about its frequency, characteristics and associated factors in SMA. OBJECTIVE: To characterize fatigue in SMA patients receiving nusinersen, identify associated factors and evaluate fatigue as potential patient-reported outcome measure (PRO). METHODS: We assessed fatigue in adults with genetically confirmed 5q-SMA in a prospective longitudinal monocentric study using the Fatigue Severity Scale (FSS) and the Multidimensional Fatigue Inventory (MFI). Factors associated with fatigue including health-related quality of life (HRQOL) were evaluated. RESULTS: 75% of participants were abnormally fatigued with highest scores in the dimensions physical, followed by general fatigue and reduced activity. 53% agreed that fatigue was among their three most disabling symptoms. Reduced activity was reported more extensively by participants with ≥ 4 copies of the survival of motor neuron 2 gene and better motor function. General and mental fatigue correlated positively with age and disease duration. HRQOL was inversely correlated with physical fatigue, which was not associated with disease or participant characteristics. During 14 months of nusinersen treatment, fatigue measures remained mostly stable with a trend towards improvement in reduced activity, general and physical fatigue. CONCLUSION: Fatigue is a frequent and relevant complaint in adult SMA patients. Fatigue should be taken into consideration as additional outcome measure, but needs further evaluation in a larger patient cohort over a longer observation period.
BACKGROUND: Efficacy of nusinersen in adult 5q-spinal muscular atrophy (SMA) patients regarding motor function has recently been demonstrated. However, additional outcome measures are needed to capture non-motor improvements. Fatigue is a common and disabling symptom in neurologic diseases, but little is known about its frequency, characteristics and associated factors in SMA. OBJECTIVE: To characterize fatigue in SMApatients receiving nusinersen, identify associated factors and evaluate fatigue as potential patient-reported outcome measure (PRO). METHODS: We assessed fatigue in adults with genetically confirmed 5q-SMA in a prospective longitudinal monocentric study using the Fatigue Severity Scale (FSS) and the Multidimensional Fatigue Inventory (MFI). Factors associated with fatigue including health-related quality of life (HRQOL) were evaluated. RESULTS: 75% of participants were abnormally fatigued with highest scores in the dimensions physical, followed by general fatigue and reduced activity. 53% agreed that fatigue was among their three most disabling symptoms. Reduced activity was reported more extensively by participants with ≥ 4 copies of the survival of motor neuron 2 gene and better motor function. General and mental fatigue correlated positively with age and disease duration. HRQOL was inversely correlated with physical fatigue, which was not associated with disease or participant characteristics. During 14 months of nusinersen treatment, fatigue measures remained mostly stable with a trend towards improvement in reduced activity, general and physical fatigue. CONCLUSION:Fatigue is a frequent and relevant complaint in adult SMApatients. Fatigue should be taken into consideration as additional outcome measure, but needs further evaluation in a larger patient cohort over a longer observation period.
Authors: Sally Dunaway Young; Jacqueline Montes; Samantha S Kramer; Bernadette Podwika; Ashwini K Rao; Darryl C De Vivo Journal: J Neuromuscul Dis Date: 2019
Authors: Tim Hagenacker; Andreas Hermann; Christoph Kamm; Maggie C Walter; Markus Weiler; René Günther; Claudia D Wurster; Christoph Kleinschnitz Journal: Fortschr Neurol Psychiatr Date: 2019-12-17 Impact factor: 0.752
Authors: Tim Hagenacker; Claudia D Wurster; René Günther; Olivia Schreiber-Katz; Alma Osmanovic; Susanne Petri; Markus Weiler; Andreas Ziegler; Josua Kuttler; Jan C Koch; Ilka Schneider; Gilbert Wunderlich; Natalie Schloss; Helmar C Lehmann; Isabell Cordts; Marcus Deschauer; Paul Lingor; Christoph Kamm; Benjamin Stolte; Lena Pietruck; Andreas Totzeck; Kathrin Kizina; Christoph Mönninghoff; Otgonzul von Velsen; Claudia Ose; Heinz Reichmann; Michael Forsting; Astrid Pechmann; Janbernd Kirschner; Albert C Ludolph; Andreas Hermann; Christoph Kleinschnitz Journal: Lancet Neurol Date: 2020-03-18 Impact factor: 44.182
Authors: S Singer; S Kuhnt; R Zwerenz; K Eckert; D Hofmeister; A Dietz; J Giesinger; J Hauss; K Papsdorf; S Briest; A Brown Journal: Br J Cancer Date: 2011-07-12 Impact factor: 7.640
Authors: Alma Osmanovic; Gresa Ranxha; Mareike Kumpe; Claudia D Wurster; Benjamin Stolte; Isabell Cordts; René Günther; Maren Freigang; Lars H Müschen; Camilla Binz; Andreas Hermann; Marcus Deschauer; Paul Lingor; Albert C Ludolph; Tim Hagenacker; Olivia Schreiber-Katz; Susanne Petri Journal: Ther Adv Neurol Disord Date: 2021-03-05 Impact factor: 6.570
Authors: Camilla Binz; Alma Osmanovic; Susanne Petri; Olivia Schreiber-Katz; Nele H Thomas; Benjamin Stolte; Maren Freigang; Isabell Cordts; Ramona Griep; Zeljko Uzelac; Claudia D Wurster; Christoph Kamm; Hannah A Siegler; Gary Wieselmann; Andreas Hermann; Paul Lingor; Marcus Deschauer; Albert C Ludolph; Thomas Meyer; René Günther; Tim Hagenacker Journal: Ann Clin Transl Neurol Date: 2022-02-22 Impact factor: 4.511